RxDoctor Payments Data

Christina Avdoulos

Medical · Roslyn, NYNPI 1609816784

Payments from drug & device makers

$2,075in general payments, 2019–2025

Across 66 payments — averaging $31.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$303
  • Boston Scientific$270
  • Amgen$247
  • Novartis$223
  • Heartflow, Inc.$130
  • Inspire Medical Systems, Inc.$120
  • plus $782 from 19 others

What the payments were for

  • Food & beverage$2,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,075 in reported general payments places this provider in the 75th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$62,405
Medicare patients
335
Services billed
1,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban270$378,517
EntrestoSacubitril/Valsartan180$264,176
XareltoRivaroxaban69$88,589
FarxigaDapagliflozin Propanediol75$86,710
Repatha SureclickEvolocumab66$49,203
BrilintaTicagrelor41$40,000
JardianceEmpagliflozin17$23,058
MounjaroTirzepatide21$20,672
VascepaIcosapent Ethyl23$13,766
Repatha SyringeEvolocumab21$12,430
Metoprolol Succinate591$9,623
Atorvastatin Calcium729$6,179
Dabigatran EtexilateDabigatran Etexilate Mesylate12$4,616
Ranolazine ErRanolazine44$4,414
Ezetimibe171$3,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$378,517270 claims
NovartisEntresto$223$264,176180 claims
AstraZenecaFarxiga, Brilinta$19$126,711116 claims
Johnson & JohnsonXarelto$67$88,58969 claims
Boehringer IngelheimJardiance$58$23,05817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,395 medical providers in New York.

Other medical in Roslyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →